TOKYO -- Daiichi Sankyo will finally put an end to its six years with Indian subsidiary Ranbaxy Laboratories after quality-control issues turned the purchase into a major liability for the Japanese pharmaceutical company.
Business
Daiichi Sankyo to end 6-year Ranbaxy debacle with sale
Daiichi Sankyo President Joji Nakayama charts an exit strategy.
Latest on Business
